Opiate and cocaine addictions: challenge for pharmacotherapies.
about
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addictionDeltaFosB: a sustained molecular switch for addictionEvidence-based practices for substance use disordersNew developments in the pharmacotherapy of cocaine abuseReduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addictionAutoradiographic evidence that prolonged withdrawal from intermittent cocaine reduces mu-opioid receptor expression in limbic regions of the rat brain.Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.Pharmacotherapy of addictions.Chronic stress, drug use, and vulnerability to addiction.Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy.Opiates inhibit neurogenesis in the adult rat hippocampus.Relational Psychotherapy Mothers' Group: a developmentally informed intervention for at-risk mothersA possible mechanism underlying the effectiveness of acupuncture in the treatment of drug addiction.Modeling stress and drug craving in the laboratory: implications for addiction treatment development.Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments.Effects of acute "binge" cocaine on preprodynorphin, preproenkephalin, proopiomelanocortin, and corticotropin-releasing hormone receptor mRNA levels in the striatum and hypothalamic-pituitary-adrenal axis of mu-opioid receptor knockout mice.Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.Effects of cocaine in rats exposed to heroin.Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use.Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users.Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment.High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients.Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis.
P2860
Q24320057-2BF14221-CB96-42EE-B773-BC86F1E2DA4BQ24555194-44840175-2EA3-40D7-83B6-1827CA6AB9E7Q24614016-090714EE-09F3-4D9E-832C-D8739EA4AA2DQ28302782-2FDEC5A6-9BBF-4500-AC2A-CA27A2CA97FAQ28363073-736DD2C5-0D4A-4CB2-8237-63E921BB0E4EQ31406604-B5D2D2DF-135D-4632-B7BF-2B230385808FQ33643136-C0637A05-8E5E-4DBD-AAC4-D36B3C715AD6Q34810395-8D40DDCF-A793-43BF-BE3D-8E60A97AF2F9Q34875333-C46BDAF3-A5AA-4852-8BFD-6FD0941C2D13Q35143923-EE8AE4F8-99E2-43D2-B4B5-6034EF0DDF0EQ35163722-E918F2DF-5A9C-496E-93EF-D2D1250315CEQ35855814-31C9BF1C-0F67-493A-873F-C64A80834457Q36862752-A1F23E82-222D-48F0-B702-345819A51DC9Q37306081-F71A473E-4372-43C5-BF97-96FB9F4F0FE0Q41556993-6D20164B-BFA4-483B-B6A9-90334DCF93BFQ44069088-102484BB-0AE6-4C5C-894C-444719EFB899Q44474417-5BEF533B-2594-4655-950D-4A532A04B8E5Q44573133-709CDF56-CAB3-46E0-89A8-7F8796B3BD4CQ44811425-ED0A3F70-84A2-4705-B3F2-F208D3C689C2Q46433374-301CF032-1069-43D1-BD82-1429F1E549B5Q47097008-0D82D87D-0054-4AA6-BF66-3A0BBD01F481Q48709433-5A9057FE-3E08-4155-B38B-34A2DA420A1FQ49113846-6EC3FF13-CF44-4BFF-ACA9-51F843EA3C10
P2860
Opiate and cocaine addictions: challenge for pharmacotherapies.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Opiate and cocaine addictions: challenge for pharmacotherapies.
@en
type
label
Opiate and cocaine addictions: challenge for pharmacotherapies.
@en
prefLabel
Opiate and cocaine addictions: challenge for pharmacotherapies.
@en
P1476
Opiate and cocaine addictions: challenge for pharmacotherapies.
@en
P2093
P304
P356
10.1016/S0091-3057(96)00440-6
P407
P577
1997-07-01T00:00:00Z